EDUCATION AND TRAINING

ACADEMIC APPOINTMENTS

RESEARCH ACTIVITY

A. Major Research Interests
Lung vascular cell biology and pathology Signal transduction pathways in regional vascular disease.
Novel pharmacotherapeutic approaches in cancer.
  

B. Current Research Support
“DNA lesions and gene expression in hypoxic lung disease,” National Institutes of Health, P.I: M.N. Gillespie, $718,542, 1998-2002 (HL 58234).
“Mitochondrial DNA integrity and endothelial cell oxidant stress” National Institutes of Health, P.I: M.N. Gillespie, $1,125,000, 10/01/01-9/31-06 (Project #3 in PO1 HL66299: PI. T. Stevens).
 

C. Pending Grant Application

“Lung cell genomic threats from physiological signaling.” National Institutes of Health, P.I: M.N. Gillespie, $1,125,000, 2003-2008
 

D. Previous Grant Support

"Hypoxic pulmonary hypertension and polyamines,” National Institutes of Health, P.I: M.N. Gillespie, $890,490, 1996-2002 (HL 38495).

"Mechanisms of head trauma-induced lung injury", National Institutes of Health Program Project Grant entitled "Mechanisms of brain injury and its systemic sequalae." P.I: A.B. Young, Project #4 Leader: M.N. Gillespie, $446,541, 1994-1999. (1PO1 NS31220)
 

"Epidermal growth factor in pulmonary hypertension", National Institutes of Health, P.I: M.N. Gillespie $434,843, 1991-1996 (1RO1 HL43831).
 

"Mechanisms of interstitial pneumonitis in murine AIDS", National Institutes of Health, P.I: D.A. Cohen, Co-I: Dr. Gillespie. $651,839, 1994-1998. (1RO1 HL53246)
 

"Monocrotaline toxicity and transforming growth factor-ß", National Institutes of Health, P.I: Dr. J. Olson, Co-I: Dr. Gillespie, $608,941, 1990-1995. (1RO1 HL44084)
 

"Polyamines in monocrotaline-induced pneumotoxicity", National Institutes of Health, P.I: Dr. J. Olson, Co-I: Dr. Gillespie, $573,923, 1989-1994. (RO1 HL36404)
 

"Hypoxic pulmonary hypertension and polyamines", National Institutes of Health, Research Career Development Award, $276,000, 1988-1993. (KO4  HL02174)
 

"Regulation of alveolar type II cell phenotype during cardiopulmonary dysfunction", American Heart Association-Kentucky Affiliate, P.I: R.C. Baybutt (M.N. Gillespie is the mentor on this Fellowship), $20,000, 1993-1994.
 

"Cellular pathology of pulmonary hypertension", American Heart Association-Kentucky Affiliate, P.I: L.P. Sanders (M.N. Gillespie is the mentor on this Fellowship), $20,000, 1991-1992.
 

"Neutrophils and coronary endothelial injury", American Heart Assoc., National Center , $89,000, 1988-1991.
 

"The renin-angiotensin system in experimental pulmonary hypertension",  American Heart Association, Kentucky Affiliate, P.I: Dr. L. Cassis, Co-I: Dr. Gillespie, $17,000, 1990-1991.
 

"Hypoxic pulmonary hypertension and polyamines," National Institutes of Health, $243,295, 1987-1991. (R29 HL38495)
 

"The disposition of cibenzoline in the isolated, perfused heart and possible interaction with digoxin", Hoffmann-LaRoche, Inc., $3800, 1983.
 

"Myocardial disposition and pharmacodynamics of the novel positive inotropic agent, RO 13-6438", Hoffmann-LaRoche, Inc., $12,400, 1983.
 

"Myocardial disposition and pharmacodynamics of cibenzoline in the dog", Hoffmann-LaRoche, Inc., $11,000, 1983.
 

"Influence of atherosclerosis on myocardial disposition of cibenzoline in perfused rabbit hearts", Hoffmann-LaRoche, Inc., $12,800, 1983.
 

"Platelet-dependent acute myocardial ischemia: Mechanisms of induction and exacerbation by nicotine", Tobacco and Health Res. Inst., $43,927, 1983-1985.  
 

"Atherosclerosis-induced changes in coronary vasoreactivity", American Heart Assoc., Kentucky Affiliate, $14,100, 1983-1984.  
 

"Vascular reactivity in pulmonary hypertension", American Heart Assoc., Kentucky Affiliate, P.I: Dr. R.J. Altiere, Co.-I: Dr. Gillespie, $13,478, 1983-1984.
 

"Neutrophil-induced myocardial injury", American Heart Assoc., Kentucky Affiliate, $14,893, 1984-1985.  
  

"Biochemical mechanisms in pulmonary hypertension", American Heart Assoc., Kentucky Affiliate, P.I: Dr. R. Altiere, Co.-I: Dr. Gillespie, $19,472, 1984-1985.  
  

"Nicotine and neutrophils in heart disease- A pilot study", Tobacco and Health Research Institute, P.I: Dr. M. Jay, Co.-I: Dr. Gillespie, $24,383, 1984-1985.  
  

"Coronary vasospasm in atherosclerotic rabbits", American Heart Assoc., Kentucky Affiliate, $17,000, 1985-1986.  
 

"Mechanism of neutrophil uptake in ischemic myocardium", American Heart Assoc., Kentucky Affiliate, P.I: Dr. M. Jay, Co.-I: Dr. Gillespie, $13,299, 1985-1986.
 

"Clinically relevant models of pulmonary hypertension", American Heart Assoc., Kentucky Affiliate, P.I: Dr. C. Cottrill, Co.-I: Dr. Gillespie, $17,352, 1985-1986.  
 

"Interactions between nicotine and polymorphonuclear leukocytes in emphysemagenesis", Tobacco and Health Research Institute, $14,565, 1985-1986.  
 

"Prostaglandin E1 in acute lung injury", The Upjohn Co., $15,000, 1985-1986.
  

"Pharmacodynamics of prostaglandin E1 in acute lung injury", The Upjohn Co., $48,600, 1986-indefinite.
  

"Lung polyamines in congenital heart disease", American Heart Assoc., Kentucky Affiliate, P.I: Dr. C. Cottrill, Co.-I: Dr. Gillespie, $16,800, 1986-1987.  
  

"Growth factors and vascular hyperreactivity", American Heart Assoc., Kentucky Affiliate, $17,233, 1987-1988.  
  

"Neonatal lung injury and pulmonary vascular hyperreactivity", American Heart Assoc., Kentucky Affiliate, P.I: Dr. T. Pauly, Co.-I: Dr. Gillespie, $16,500, 1987-1988.
  

"Inflammation in neonatal lung injury", American Lung Association, P.I; Dr. T. Pauly, Co. -I: Dr. Gillespie, $16,000.1987-1989.  
 

"Intramural inflammation and coronary spasm", American Heart Assoc., Kentucky Affiliate, PI: Dr. D. Booth, Co.-I: Dr. Gillespie, $17,800, 1987-1988.
 

"Polyamines in hypoxic pulmonary hypertension", Cystic Fibrosis Foundation, $60,000, 1986-1989.
 

"Polyamines in monocrotaline-induced pneumotoxicity", National Institutes of Health, P.I: Dr. J. Olson, Co.-I: Dr. Gillespie,  $238,417, 1986-1989.
 

"Nicotine and neutrophils in heart disease: Role of membrane fluidization", Tobacco and Health Research Institute, P.I: Dr. M. Jay, Co.-I: Dr. Gillespie, $155,464, 1986-1989.
 

"Platelet Activating Factor in neonatal persistent pulmonary hypertension", American Heart Assoc., Kentucky Affiliate, P.I: Dr. T.H. Pauly, Co-I: Dr. Gillespie, $17,889, 1988-1989.
 

"Exacerbation of coronary vasospasm by hypercholesterolemia", American Heart Assoc., Kentucky Affiliate, P.I: Dr. D.C. Booth, Co-I: Dr. Gillespie, $16,892, 1988-1989.
 

"Nicotine and free radicals in cigarette smoke-augmented pulmonary emphysema", Tobacco and Health Research Institute, P.I: Y-H Lai, Co.-I: M.N. Gillespie, $29,858, 1988-89.
 

"Bilirubin protects the neonate from oxidant-induced lung injury", American Heart Association, Kentucky Affiliate, P.I: Dr. T. Pauly, Co-I: Dr. Gillespie, $17,000, 1990-1991.
 

"Characterization of a murine model of AIDS-associated pulmonary hypertension", UKMC Small Research Grant, P.I: D.A. Cohen, Co-I: M.N. Gillespie, $9800, 1991-1992.
 

E. PUBLICATIONS (Full Papers)

1. Gillespie, M.N., L. Diamond, J. Newburger, and H.B. Kostenbauder.  The effects  of ion pair formation on the antimuscarinic activity of methantheline.  Experientia 33: 936-937, 1977.

2. Calkins, J., R. Ballard, and M.N. Gillespie. Ultraviolet light-induced reactivation of alpha-irradiated yeast cells. Rad. Res. 73:440-451,1978.

3. Gillespie, M.N., and L. Diamond. Spasmogenic activity of tobacco smoke  components on coronary arteries: A possible link between cigarette smoking and ischemic heart disease. Proc. Fifth Tobacco and Health Workshop Conference. University Press of Kentucky , pp 213-232, 1979.

4. Gillespie, M. N., K.E. Niehaus, I.W. Roger, and L. Diamond. Sodium dependent relaxation in arterial smooth muscle. Clin. Exp. Physiol. and Pharmacol. 8: 209-214, 1981.

5. Gillespie, M.N., J.E. Atkinson, J.A.Turbek, and L. Diamond. Propanolol and sotalol augment the coronary vasodilatory activity of prostacyclin in isolated rabbit hearts. Eur. J. Pharmacol. 75:155-158, 1981.

6. Diamond, L., J.L. Szarek, and M.N. Gillespie. Evidence against a  neurotransmitter role for Substance P in the lung nonadrenergic inhibitory nervous system. Peptides 3: 27-29, 1982.

7. Diamond, L. and M.N. Gillespie. The lung nonadrenergic inhibitory nervous system. Trends in Pharmacol. Sci. 3: 237-239, 1982.

8. Wagner, W.W., R.L. Capen, M.N. Gillespie, L.P. Latham, and J. Gunther. Direct measurement of pulmonary capillary transit time. Science  218:  379-380, 1982.

9. Diamond, L., J.L. Szarek, M.N. Gillespie, and R.J. Altiere. Nonadrenergic control of the lung,  pp 273-278. In: Systemic Role of Regulatory Peptides. J. M. Pollack and S. Bloom (eds.), F. K. Schattauer Vertag-Stuttgart, New York , 1982.

10. Diamond, L., J.L. Szarek, M.N. Gillespie, and R.J. Altiere. In vivo bronchodilator activity of vasoactive intestinal peptide. Am. Rev. Resp. Dis. 128: 827-832, 1983.

11. Gillespie, M.N., B.D. Bowdy, and C.N. Reinsel. Pulmonary vasoactivity of lung endocrine cell-related peptides. Peptides 5: 21 -24, 1984.

12. Gillespie, M.N., B.D. Bowdy, C.N. Reinsel, E.T. Iwamoto, and P.A. Crooks. Leu-enkephalin provokes naloxone-insensitive pulmonary vasoconstriction. Life Sci. 34: 1177-1182, 1984.

13. Gillespie, M.N., J.M. Evans, R.M. Rountree, and C.F. Knapp.  Attenuation of vagal nonadrenergic tachycardia by naloxone. Eur. J. Pharmacol. 101: 275-279, 1984.

14. Saxon, D.J., L. Diamond, and M.N. Gillespie. Chronic administration of water soluble tobacco smoke extract or nicotine fails to influence porcine coronary artery reactivity. Toxicology 32: 85-91,1984.

15. Gillespie, M.N., T.B. Felder, S.R. Blanford, C.N. Reinsel, and H.B.  Kostenbauder Pulmonary pharmacodynamics of verapamil. J. Cardiovas. Pharmacol. 6: 802-807, 1984.

16. Olson, J.W., A.D. Hacker, R.J. Altiere, and M.N. Gillespie. Polyamines  and the development of monocrotaline-induced pulmonary hypertension.   Am. J. Physiol. 247: H682-H685, 1984.

17. Olson, J.W., R.J. Altiere, and M.N. Gillespie. Prolonged elevation in rat lung ornithine decarboxylase in monocrotaline-induced pulmonary hypertension. Biochem. Pharmacol. 33: 3633-3637, 1984.

18. Crooks, P.A., B.D. Bowdy, C.N. Reinsel, E.T. Iwamoto, and M.N. Gillespie. Structure-activity evidence against opiate receptor involvement in leu-enkephalin-induced pulmonary vasoconstriction. Biochem. Pharmacol. 33: 4095-4098, 1984.

19. Gillespie, M.N., W.B. Frederick, R.J. Altiere, J.W. Olson, and E.C. Kimmel. Pulmonary mechanical, ventilatory, and gas exchange abnormalities in rats with monocrotaline-induced pulmonary hypertension. Exp. Lung Res. 8: 191-199, 1985.

20. Gillespie, M.N., J.W. Krechniak, P.A. Crooks, R.J. Altiere, and J.W. Olson. Metabolism of exogenous enkephalins in isolated rat lungs. J. Pharmacol. Exp. Ther. 232: 675-681, 1985.

21. McElroy, D.L., J.L. Fink,III, and M.N. Gillespie. Factors influencing pharmacy students' interest in graduate study. Am. J. Pharmaceutical Ed.  49: 163-167, 1985.

22. Crooks, P.A., J. W. Krechniak, J.W. Olson, and M.N. Gillespie. High performance liquid chromatographic analysis of leu-enkephalin in isolated rat lung. J. Pharm. Sci. 74: 1010-1012, 1985.

23. Olson, J.W., J.E. Atkinson, A.D. Hacker, R.J. Altiere, and M.N. Gillespie. Suppression of polyamine synthesis prevents monocrotaline-induced pulmonary edema and arterial medial thickening. Tox. Appl. Pharmacol. 81: 91-99, 1985.

24. Gillespie, M.N., J.O. Owasoyo, W.N. O'Connor, J. Kiritsy-Roy, and Glen N. Van Loon. Exaggerated nicotine-induced norepinephrine release from atherosclerotic rabbit hearts. Toxicol. 37: 147-157, 1985.

25. Gillespie, M.N., K.K. Dyer, W.N. O'Connor, J.W. Olson, and R.J. Altiere. Alpha diflouromethylornithine, an inhibitor of polyamine synthesis, attenuates monocrotaline-induced pulmonary vascular hyperresponsiveness in isolated perfused rat lungs. Res. Com. Chem. Path. Pharm. 50: 365-377, 1985.

26. Gillespie, M.N. and B.D. Bowdy. Platelet activating factor blunts pulmonary vascular reactivity in isolated buffer perfused rat lungs. J. Pharmacol. Exp. Ther. 236: 396-402, 1986.

27. McNamara, P.J., K.R. Brouwer, and M.N. Gillespie. Autacoid binding to serum  proteins: Interaction of platelet activating factor with human serum alpha-1-acid glycoprotein. Biochem. Pharmacol. 35: 621-624, 1986.

28. Gillespie, M.N. J.O. Owasoyo, I.F. McMurtry, and R.F. O'Brien.  Sustained coronary vasoconstriction provoked by a peptidergic substance released from endothelial cells in culture. J. Pharmacol. Exp. Ther. 236: 339-343, 1986.

29. Olson, J.W., A.D. Hacker, J.A. Atkinson, R.J. Altiere, and M.N. Gillespie. Polyamine content in rat lung during development of hypoxia-induced pulmonary hypertension. Biochem. Pharmacol. 35: 714-716, 1986.

30. Altiere, R.J., J.W. Olson, and M.N. Gillespie. Altered pulmonary vascular smooth muscle responsiveness during evolution of monocrotaline-induced pulmonary hypertension in rats. J. Pharmacol. Exp. Ther. 236: 390-395, 1986.

31. Gillespie, M.N., W.N. O'Connor, C.N. Reinsel, J.W. Olson, and R.J. Altiere. Vascular hyperresponsiveness in perfused lungs from monocrotaline-treated rats. Am. J. Physiol. 251: H109-H114, 1986.

32. Szarek, J.L., M.N. Gillespie, R.J. Altiere, and L. Diamond. Reflex activation of the nonadrenergic, noncholinergic inhibitory system in feline airways. Am. Rev. Resp. Dis. 133: 1152-1159, 1986.

33. Jay, M., S. Kojima, and M.N. Gillespie. Nicotine augments superoxide anion by activated human neutrophils. Tox. Appl. Pharmacol., 86: 484-487, 1986.

34. Gillespie, M.N., S. Kojima, M. Kunitomo, and M. Jay. Coronary and myocardial effects of activated neutrophils in perfused rabbit hearts. J. Pharmacol. Exp. Ther., 239: 836-840, 1986.

35. Goldblum, S.E., D.A. Cohen, M.N. Gillespie, and C.J. McClain.   Interleukin 1-induced granulocytopenia and pulmonary leukostasis in rabbits. J. Appl. Physiol., 62: 122-128, 1987.

36. Atkinson, J.E., J.W. Olson, R.J. Altiere, and M.N. Gillespie. Evidence that hypoxic pulmonary vascular remodeling is polyamine dependent. J. Appl. Physiol., 62: 1562-1568 1987.

37. Booth , D.C. , M.R. Cunningham, R.M. Rountree, and M.N. Gillespie.  Coronary arteriographic and electrocardiographic effects of ergonovine and indomethacin in rabbits abruptly withdrawn from chronic nitroglycerin treatment. Am. Heart J., 114: 343-349, 1987.

38. Gillespie, M.N., J.O. Owasoyo, S. Kojima, and M. Jay. Prolonged nicotine treatment or tobacco smoke exposure enhances neutrophil superoxide release and chemotaxis in rats. Toxicol., 45: 45-52, 1987.

39. Gillespie, M.N., S. Kojima, J.O. Owasoyo, H-H. Tai, and M. Jay.  Hypoxia provokes leukotriene-dependent neutrophil uptake in perfused rabbit hearts. J. Pharmacol. Exp. Ther., 241: 812-816, 1987.

40. Gillespie, M.N., C.G. Moore, C.E. Wright, and W.N. O'Connor. Salutary effects of prostaglandin E1 in hydrogen peroxide-induced lung injury. J. Pharmacol. Exp. Ther., 241: 1-5, 1987.

41. Goldblum, S.E., M. Jay, K. Yoneda, D.A. Cohen, and M.N. Gillespie. Monokine-induced acute lung injury in rabbits. J. Appl. Physiol., 63: 2903-2910, 1987.

42. Gillespie, M.N., D.C. Booth, B.J. Friedman, M.R. Cunningham, and A.N. DeMaria. Provocation of coronary vasospasm in rabbits by the inflammatory cell stimulant formylmethionyl-leucyl-phenylalanine. Am. J. Physiol. 254: H481-H486, 1988.

43. Gillespie, M.N., D.A. Cohen, C.J. McClain, and S.E. Goldblum.   Interleukin-1 like activity in the lungs of rats with monocrotaline-induced pulmonary hypertension. Proc. Soc. Exp. Biol. Med. 187: 26-32, 1988.

44. Owasoyo, J.O., M. Jay, and M.N. Gillespie. Nicotine promotes neutrophil sequestration in isolated rabbit hearts. Tox. Appl. Pharmacol. 92: 86-94, 1988.

45. Cottrill, C.M., G.L. Johnson, and M.N. Gillespie. Echocardiographic detection of pulmonary hypertension in anesthetized rats. Res. Commun. Chem. Path. Pharmacol. 60: 188-195,1988.

46. Gillespie, M.N., R.J. Altiere, and J.W. Olson. Polyamines in pulmonary hypertension. Amer. J. Pharm. Educ. 52: 180-188, 1988.

47. Olson, J.W., B. Hennig, R.J. Altiere, S.E. Goldblum, and M.N. Gillespie.  Growth factors and diacylglycerol stimulate pulmonary vascular endothelial cell ornithine decarboxylase activity. Chest, 93: 168S, 1988.

48. Pauly, T.H., B.D. Bowdy , C.A. Haven, S.B. Barr, and M.N. Gillespie.  Evidence for hydroxyl radical involvement in group B streptococcus-induced pulmonary hypertension and arterial hypoxemia. Ped. Research, 24: 735-539, 1988.

49. Orlinska, U., J.W. Olson, and M.N. Gillespie. Polyamine synthesis in macroscopic pulmonary arteries from rats with monocrotaline-induced pulmonary hypertension. Res. Commun. Chem. Path. Pharmacol., 62: 187-194, 1988.

50. Olson, J.W., S.H. Allen-Gebb, U. Orlinska, and M.N. Gillespie.  Polyamine synthesis in rat lungs injured with alpha naphthylthiourea. Toxicology, 55: 317-326, 1989.

51. Gillespie, M.N., D.A. Cohen, J.W. Olson, C.J. McClain, and S.E. Goldblum. Monokine-induced lung injury in rats: Similarities to monocrotaline-induced pneumotoxicity. Toxicol. Appl. Pharmacol. 98: 134-143, 1989.

52. McNamara, P.J., R.C. Jewell, and M.N. Gillespie. The interaction of alpha-1-acid glycoprotein with endogenous autacoids, in particular, platelet activating factor. In: Genetics, Biochemistry, Physiological Functions, and Pharmacology of Alpha-1-Acid Glycoprotein. Alan R. Liss, Inc., New York , NY , 1989.

53. Orlinska, U., J.W. Olson, S. Allen-Gebb, and M.N. Gillespie. Acetylated polyamines in lungs from rats with monocrotaline-induced pneumotoxicity.  Fund. Appl. Toxicol., 13: 277-284, 1989.

54. Olson, J.W., U. Orlinska, and M.N. Gillespie. Polyamine synthesis blockade in monocrotaline-induced pulmonary hypertension. Biochem. Pharmacol. 38: 2903-2910, 1989.

55. Rippetoe, P.E., J.W. Olson,. R.J. Altiere, T.H. Pauly, and M.N. Gillespie. Epidermal growth factor augments reactivity to angiotensin II in the rat pulmonary circulation. Amer. Rev. Resp. Dis., 140: 821-824, 1989.

56. Gillespie, M.N., P.E. Rippetoe , C.A. Haven, R-T. Shiao, U. Orlinska, B.E. Maley, and J.W. Olson. Epidermal growth factor and polyamines in monocrotaline-induced pulmonary hypertension. Am. Rev. Resp. Dis. 140: 1463-1466, 1989.

57. Bowdy, B.D., S.J. Marple, L.S. Shook, T.H. Pauly, J.D. Coonrod, and M.N. Gillespie. Oxygen radical-dependent bactericidal activity and pulmonary hypertension in septic piglets. Am. Rev. Resp. Dis. 141: 648-653, 1990.

58. Bowdy, B.D., S.J. Marple, K. Yoneda, J.D. Coonrod, and M.N. Gillespie.  Organ-specific deposition of group B streptococci in infant piglets: evidence that pulmonary hypertension results from a direct interaction with target cells in the lung. Pediatr. Res. 27: 344-348, 1990.

59. Shook, L.A. , T.H. Pauly, S.L. Marple, S.J. Horstman, H-H. Tai, B.D. Bowdy, and M.N. Gillespie. Group B Streptococci promotes oxygen radical-dependent thromboxane accumulation in young piglets. Pediatr. Res. 27: 349-352, 1990.

60. Shook, L.A. , T.H. Pauly, S.L. Marple, S.J. Horstman, B.D. Bowdy, and M.N. Gillespie. Dimethylthiourea reverses group B streptococcus-induced pulmonary hypertension and arterial hypoxemia in young piglets. Amer. J. Med. Sci. 300: 29-32, 1990.

61. Shiao, R-T, U. Orlinska, J.W. Olson, and M.N. Gillespie. Mechanisms of lung polyamine accumulation in chronic hypoxic pulmonary hypertension:  Role of ornithine decarboxylase and polyamine transport. Am. J. Physiol:  Lung Cell Molec. Physiol. 259: L351-358, 1990.

62. Numan, N.A., M.N. Gillespie, and R.J. Altiere. Pulmonary  vasorelaxant activity of atrial natriuretic peptides. Pulm. Pharmacol. 3: 29-34, 1991.

63. Numan, N.A., M.N. Gillespie, and R.J. Altiere. Pulmonary clearance of atrial natriuretic peptides. Pulm. Pharmacol. 3: 25-28, 1991.

64. Lai, Y-L., J.W. Olson, and M.N. Gillespie. Ventilatory dysfunction precedes pulmonary hypertension in monocrotaline-treated rats. J. Appl. Physiol. 70: 561-566, 1991.

65. Gillespie, M.N., S.M. Aziz, and T.H. Pauly. Pulmonary intravascular macrophages: Cellular Targets of opportunity for inhaled drugs. Proceedings of the Second Symposium on Respiratory Drug Delivery, CRC Press, 1991.

66. Pauly, T.H., M. Smith, and M.N. Gillespie. Does bilirubin protect the neonate against oxidant-mediated lung injury. Biol. of the Neonate  60: 320-326, 1991.

67. Pauly, T.H., S.M. Aziz, S.J. Horstman, and M.N. Gillespie. Impact of cyclooxygenase and thromboxane synthase blockade on lung microbicidal activity directed against group B streptococci in infant piglets. Pediatr. Res. 31: 14-17, 1991.

68. Gillespie, M.N., S.S. Arcot, D.W. Lipke, and J.W. Olson. Pharmacologic targets in hypertensive pulmonary vascular disease. Med. Toracina 14: 81-93, 1992.

69. Cottrill, C.M., W.N. O'Connor, R.M. Fitz, and M.N. Gillespie. Pulmonary vascular remodeling in rats with unilaterally-banded lobar pulmonary veins.  Cardiol. in the Young 2: 121-128, 1992.

70. Haven-Doll, C., J.W. Olson, and M.N. Gillespie. Regulation of polyamine transport and ornithine decarboxylase activity in hypoxic bovine main pulmonary artery smooth muscle cells. Am. J. Resp. Cell Mol. Biol., 7: 286-292, 1992.

71. Cassis, L.A. , P.E. Rippetoe, R.M. Fitz, E.E. Soltis, and M.N. Gillespie.  Effect of Losartan, a non-peptide angiotensin II receptor antagonist, on pulmonary hypertension in monocrotaline treated rats. J. Pharmacol. Exp. Ther. 262: 1168-1172, 1992.

72. Aziz, S.M., E. Sandefer, T.H. Pauly, and M.N. Gillespie. Scintigraphic examination of pulmonary group B streptococcus uptake and its relation to lung neutrophil infiltration. Biol. Neonate, 63: 86-95, 1993.

73. Aziz, S.M., T.H. Pauly, and M.N. Gillespie. Intrinsic microbicidal activity of the pulmonary circulation and its link to sepsis-induced pulmonary hypertension. Pediatr. Res. 34: 32-37, 1993.

74. Lipke, D.W., S.S. Arcot, M.N. Gillespie, and J.W. Olson. Temporal alterations in specific basement membrane components in lungs from monocrotaline-treated rats. Am. J. Resp. Cell Mol. Biol. 9: 418-428, 1993.

75. Arcot, S.S., D.W. Lipke, M.N. Gillespie, and J.W. Olson. Alterations of growth factor transcripts in rat lungs during development of monocrotaline-induced pulmonary hypertension. Biochem. Pharmacol., 46: 1086-1091, 1993.

76. Aziz, S,M., K.L. Harrod, J.W. Olson, and M.N. Gillespie. Multiple polyamine transport pathways in bovine pulmonary artery smooth muscle cells: Regulation by hypoxia. Am. J. Resp. Cell Mol. Biol. 10: 160-166, 1994.

77. Bummer, P.M., L.P. Sanders, T.H. Pauly, and M.N. Gillespie.  Inactivation of clinically relevant surfactant preparations by serum albumin.  Amer. J. Med. Sci. 307: 401-414, 1994.

78. Gillespie, M.N., C.L. Hartsfield, W.N. O'Connor, and D.A. Cohen. Pulmonary hypertension in a murine model of the acquired immunodeficiency syndrome. Am. J. Respir. Crit. Care Med. 150: 194-199, 1994.

79. Bummer, P.M., J.A. Baughn, L.P. Sanders, K.R. Tarrence, W.N. O'Connor, J.W. Olson, and M.N. Gillespie. Surfactant disposition in monocrotaline-induced pneumotoxicity. Toxicol., 90: 53-62, 1994.

80. Aziz, S.M., J.W. Olson, and M.N. Gillespie. Sodium- and ATP-dependent regulation of polyamine transport in hypoxic pulmonary artery smooth muscle cells. Biochem. Pharmacol. 48: 1611-1618, 1994.

81. Baybutt, R.C., J.E. Smith, M.N. Gillespie, and Y-Y. Yeh. The effect of arachidonic acid and eicosapentaenoic acid on surfactant secretion by alveolar type II pneumocytes. Lipids. 29: 535-539, 1994.

82. Baybutt, R.C., S.M. Aziz, J.A. Fagerland, J.W. Olson, and M.N. Gillespie. Polyamine regulation in rat type II pneumocytes treated with the pneumotoxin, monocrotaline. Toxicol. Appl. Pharmacol. 129: 188-195, 1994.

83. Ott, L.G., C.J. McClain, M.N. Gillespie, and A.B. Young. Cytokines and metabolic dysfunction after head injury. J. Neurotrauma 11: 447-472, 1994.

84. Gillespie, M.N., D.W. Lipke, and I.F. McMurtry. Regulation of pulmonary vasomotor tone in hypertensive pulmonary vascular remodeling. In: Pulmonary Vascular Remodeling, Portland Press Research Monograph, pp: 117-148, Eds: Bishop, J.E., Reeves, J.T., and Laurent, G.J, 1995.

85. Arcot , S.A. , J.A. Fagerland, D.W. Lipke, M.N. Gillespie, and J.W. Olson. Basic fibroblast growth factor alterations during development of monocrotaline-induced pulmonary hypertension in rats. Growth Factors, 12: 121-130, 1995.

86. Aziz, S.M., M.P. Gosland, J.W. Olson, and M.N. Gillespie. A novel polymeric spermine conjugate inhibits polyamine transport in pulmonary artery smooth muscle cells. J. Pharmacol. Exp. Ther. 274: 181-186, 1995.

87. Bummer, P.M., S.M. Aziz, and M.N. Gillespie. Inhibition of pulmonary surfactant biophysical activity by cationic polyamino acids. Pharmaceut. Res. 12: 1658-1663, 1995.

88. Gillespie, M.N. and J.W. Olson. Polyamine regulatory mechanisms in hypertensive pulmonary vascular disease. ISLI Press. Washington , DC, 1996.

89. Aziz, S.M., M.N. Gillespie, P.A. Crooks, S.F. Tofiq, C.P. Tsuboi, C.P. Tsubois, J.W. Olson, and M.P. Gosland. The chemotherapeutic potential of a novel spermine transport inhibitor. J. Pharmacol. Exp. Ther., 278: 185-192, 1996.

90. Harrod, K.S., J.W. Olson, and M.N. Gillespie. Regulation of ornithine decarboxylase and S-adenosylmethionine decarboxylase by hypoxia in cultured bovine pulmonary artery smooth muscle cells. Amer. J. Physiol: Lung Cell Molec. Physiol. 271: L31-L37, 1996.

91. Cohen, D., E. Fitzpatrick, C. Hartsfield, M. Avdiushko, and M.N. Gillespie. Abnormal lung cytokine synthesis by immunodeficient T cells in murine AIDS-associated interstitial pneumonitis. Ann. N.Y. Acad. Sci. 796: 47-58, 1996.

92. Gosland, M.P., M.N. Gillespie, C.P. Tsuboi, S. Tofiq, J.W. Olson, P.A. Crooks, and S.M. Aziz.  Reversal of doxorubicin, etoposide, vinblastin, and taxol resistance in multidrug resistant human sarcoma cells by a polymer of spermine. Cancer  Chemother. Pharmacol., 37: 593-600, 1996.

93. Vyas-Somani, A., S.M. Aziz, S.A. Arcot, M.N. Gillespie, and D.W. Lipke. Temporal alterations in basement membrane components in the pulmonary vasculature of the chronically hypoxic rat; impact of hypoxia and recovery. Amer. J. Med. Sci., 312: 54-67, 1996.

94. Hartsfield, C.L., E. Fitzpatrick, D.A. Cohen, and M.N. Gillespie.  Pulmonary mechanical and immunologic dysfunction in a murine model of AIDS. Amer. J. Physiol: Lung Cell Molec. Physiol. 272: L699-L706, 1997.

95. Cohen, D.A., E.A. Fitzpatrick, C. L. Hartsfield, M.N. Gillespie, M. Avidushko, and A.M. Kaplan.  Pulmonary lymphoid cell activation and cytokine expression in murine AIDS-associated interstitial pneumonitis. Am. J. Resp. Cell Mol. Biol. 16: 153-161, 1997.

96. Cassis, L.A. , U. Shenoy, D.W. Lipke, J.A. Baughn, M. Fettinger, and M.N. Gillespie. Lung angiotensin II receptor binding characteristics during development of monocrotaline-induced pulmonary hypertension. Biochem. Pharmacol., 54: 27-3, 1997.

97. Babal, P., and M.N. Gillespie. Cultured rat pulmonary artery smooth muscle cells exhibit at least two polyamine transport phenotypes that differ morphologically and in response to hypoxia. Chest 114: 34S-35S, 1998.

98. Gillespie, M.N., D.W. Killilea, M. Solomon, P. Baba., S.P. LeDoux, and G.L. Wilson. Hypoxia causes oxidant lesions in the rat pulmonary artery smooth muscle cell VEGF gene; potential link to VEGF mRNA expression. Chest 114: 45S, 1998.

99. Parker, J.C., M.N. Gillespie, A.E. Taylor, and S.L. Martin. Capillary filtration coefficient, vascular resistance, and compliance in isolated, perfused mouse lungs. J. Appl. Physiol. 87: 1421-1427, 1999.

100. Babal, P. S.M. Manuel. J.W. Olson, and M.N. Gillespie. Cellular disposition of transported polyamines in hypoxic rat lung and pulmonary arteries. Amer. J. Physiol: Lung Cell Molec. Physiol. 278: L619-L617, 2000.

101. Killilea, D.W., R. Hester, R. Balczon, P. Babal, and M.N. Gillespie. Free radical production in hypoxic pulmonary artery smooth muscle cells. Amer. J. Physiol: Lung Cell Molec. Physiol. 279: L408-L412, 2000.

102. Chen, R., K.S. Harrod, J.W. Olson, and M.N. Gillespie. Regulation of Gadd153 mRNA expression by hypoxia in pulmonary artery smooth muscle cells. Res. Com Chem. Path. Pharmacol 108, 3-14, 2000.

103. Babál, P. M. Ruchko, J.W. Olson, and M.N. Gillespie. Interactions between agmatine and polyamine uptake pathways in rat pulmonary artery smooth muscle cells. Gen. Pharmacol. 34: 255-261, 2000.

104. Babál, P., M. Ruchko, C.C. Campbell , S. P. Gilmour, J. L. Mitchell, J. W. Olson, and M.N.. Gillespie. Regulation of ornithine decarboxylase activity and polyamine transport by agmatine in rat pulmonary artery endothelial cells. J. Pharmacol. Exp. Ther. 296: 372-377, 2001.

105. Grishko, V., M. Solomon, J.F. Breit, D.W. Killilea, S. P. LeDoux, G.L. Wilson, and  M.N. Gillespie. Hypoxia promotes oxidative base modifications in the pulmonary artery endothelial cell VEGF gene. FASEB J. 15: 1267-1269, 2001.

106. Grishko V., M. Solomon, G.L. Wilson, S.P. LeDoux, and M.N. Gillespie. Oxygen radical-induced mitochondrial DNA damage and repair in pulmonary vascular endothelial cell phenotypes. Amer. J. Physiol: Lung Cell Molec. Physiol. 280: L1300-L1308, 2001.

107. Babal, P., M. Ruchko, K. Ault-Ziel, L. Cronenberg, J.W. Olson, and M.N. Gillespie. Regulation of ornithine decarboxylase activity and polyamine import by hypoxia in pulmonary artery endothelial cells. Amer. J. Physiol: Lung Cell Molec. Physiol. 282: L840-L846, 2002.

108. Dobson, A.W.,  V. Grishko, S.P. LeDoux, M.R. Kelley, G.L. Wilson, and M.N. Gillespie. Enhanced mitochondrial DNA repair capacity protects pulmonary artery endothelial cells of oxidant-mediated death. Amer. J. Physiol: Lung Cell Molec. Physiol. 283: L205-10, 2002.

109. Ruchko, M., M.N. Gillespie, R. Weeks, J.W. Olson, and P. Babal.  Putrescine transport is required for p38 MAP kinase activation in hypoxic pulmonary artery smooth  muscle cells.  Amer. J. Physiol:  Lung Cell Molec. Physiol. 284:  L179-L284, 2003.

110. Gillespie, M.N., K.A. Ziel, M. Ruchko, P. Babal, and J.W. Olson.  Polyamine regulation in hypoxic pulmonary arterial cells.  In:  “Hypoxic pulmonary hypertension:  Cell and Molecular Mechanisms”  Ed:  J. X-J. Yuan.  Klewer Academic Publishers.  In Press, 2003.

111. Ault-Ziel, K., V. Grishko, S.P. LeDoux, G.L. Wilson, and M.N. Gillespie. Hypoxia-induced, oxidant-mediated DNA modifications in pulmonary artery smooth muscle cells; implications for regulation of gene expression.  Science, Submitted, 2003.

112. Ziel, K.A., C.C. Campbell, G.L. Wilson, and M.N. Gillespie. Ref-1/Ape is Critical For Formation of the Hypoxia-Inducible Transcriptional Complex on the Hypoxic Response Element of the Rat Pulmonary Artery Endothelial Cell VEGF Gene.  FASEB J., Submitted, 2003.

F. Abstracts

Over 160 abstracts have originated from Dr. Gillespie’s laboratory.  Complete citations are available on request.
 

OTHER PROFESSIONAL ACTIVITIES

A. Grant Reviewer / Study Section Memberships

N.I.H. Special Study Section (Neuropeptides, behavior, and cardiovascular disease, Bethesda, MD, April, 1984).  
  

American Heart Association-Kentucky Affiliate, Peer Review Committee (1987-1990; chairman, 1991-1993).  
  

American Heart Association-Kentucky Affiliate, Research Committee (1992-1994). 
  

Technical Review Panel, Nebraska Department of Health Cancer and Smoking Disease Research Program, (1987-88, 1990-92).  
 

Center for Alternatives to Animal Testing Technical Advisory Review Board (1987,1990) .
 

N.I.H. Special Study Section (Physician Scientist Awards, 1988, 2001) .
  

N.I.H. Special Study Section (STTR, SBIR grants, 2000-present) .
  

N.I.H. Special Study Section (Program Project Grants, 1991, 2000-present) .
 

N.I.H. Lung Biology and Pathology Ad Hoc Study Section, June, 1991.  
  

N.I.H. Ad Hoc Advisory Committee on Pulmonary Vascular Disease (1991) .
 

N.I.H. Site Visit Team (Program Project Grant, 1992, 2001, 2002) .
 

N.I.H. Respiratory and Applied Physiology Study Section-Ad Hoc (1992).
 

California Tobacco-related Disease Research Program- (1992, 1993) .
 

N.I.H. Lung Biology and Pathology Study Section (1993-98; Chairman, 1996-98; ad hoc member;  1998-present) .
  

March of Dimes .
  

NIH National Sickle Cell Center Review Committee (2002).
  

B. Manuscript Reviewer / Editorial Service

Toxicology and Applied Pharmacology  
 

Journal of Pharmacology and Experimental Therapeutics  
 

Journal of Applied Physiology  
 

American Journal of Physiology
 

American Review of Respiratory Disease  
 

Experimental Lung Research  
 

Life Sciences  
 

European Journal of Pharmacology
 

Research Communications in Chemical Pathology and Pharmacology  
 

Pediatric Research  
 

American Journal of Respiratory Cell and Molecular Biology  
 

Cardiovascular Research
 

Biochemical Pharmacology
 

Proceedings of the Society for Experimental Biology and Medicine  
 

Proceedings of the National Academy of Science  
 

American Journal of Respiratory and Critical Care Medicine
  

American Journal of Pathology
 

Journal of Clinical Investigation  
 

Editorial Board: American Journal of Physiology; Lung Cell and Molecular Physiology(1992-2003)  
 

International Journal of Biochemistry and Cell Biology
 

Free Radicals in Biology and Medicine  
 

FASEB J.
 

Microvascular Research

C. Invited Speaking Engagements
Dr. Gillespie has presented over 50 invited seminars. Details available on request.
 

D. Mentor for Ph.D. Students, Postdoctoral Scientists and Research Fellows
 
Mentor for Graduate Students

Faculty member of Ph.D. advisory committees:

Dr. Gillespie is, or has been, a member of over 50 Ph.D. Advisory Committees
         

Postdoctoral scientists trained:

 
E. SELECTED UNIVERSITY AND PROFESSIONAL ORGANIZATION       

Academic Performance (1985)  
  

Admissions (1985-present)
  

Alumni Affairs (1982-1984)
  

Continuing Education and Public Relations (1983-85)  
  

Honors and Recognition Day (1982-present)  
  

Research and Seminar (1984-present; Chairman, 1987-88)  
  

Ad Hoc Committee on Revising the Honor Code  
  

Medical Center Animal Care and Use Committee (1987-present; Chairman, 1989-92)  
  

Ad Hoc Pharmacology and Toxicology Search Committee (Chairman)  
  

Graduate Center for Toxicology-Director Search Committee (1988)  
  

Center for Pharmaceutical Sciences and Technology-Director Search Committee (1987-88)  
  

Graduate Center for Toxicology-Committee on Faculty Responsibilities  (Chair: 1988, 1990)  
  

Graduate Program Committee (1988)  
  

College of Pharmacy Appointment, Promotion, and Tenure Committee (1988)  
  

Medical Center Research Advisory Committee (1988-94)  
  

Graduate Center for Toxicology Faculty Search Committee (1990)  
  

Graduate Center for Toxicology Executive Committee (1991-present)  
  

University Research Professorship Selection Committee (1990)  
  

Biomedical Research Building Committee (1989-92)  
  

Graduate Fellowship Selection Committee (1990; Chairman, 1991)  
  

Clinical Research Center : Oversight Committee and Scientific Advisory Committee (1990-1994)  
  

Graduate School-Ad Hoc Committee to Evaluate the Director of the Graduate Center for Toxicology (1992; Chairman)  
  

College of Pharmacy Executive Committee (1988-1994)  
  

Academic Area Committee-Biological Sciences (promotion and tenure:  1992-1994)  
  

Graduate Executive Committee (1995-present; Director, 1996-97)  
  

College of Medicine Executive Council (1995-present)  
  

University Semester Transition Committee (1996)  
  

Faculty Representative to the Student Assembly (1997-98)  
  

Executive Council (1998-present)  
  

Basic Medical Science Chairs committee (1998-present)  
  

Director, Basic Medical Sciences Graduate Program (1999-2000)  
  

Curriculum Committee (1995-present)  
  

Search Committee for Vice President for Medical Affairs (1998)  
  

American Thoracic Society: Pulmonary Circulation Assembly Leadership Committee (2000-present)  
  

American Thoracic Society: Pulmonary Circulation Assembly Program Committee (1999-present)  
  

American Thoracic Society: Pulmonary Circulation Assembly Nominating Committee Chairman (1999-2000)